- Home
- CELC vs TGLS Comparison
CELC vs TGLS Comparison
Compare CELC & TGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELC | TGLS |
|---|---|---|
| Founded | 2011 | 1984 |
| Country | United States | Colombia |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Electronic Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2017 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CELC | TGLS |
|---|---|---|
| Price | $103.68 | $52.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $100.13 | $80.00 |
| AVG Volume (30 Days) | ★ 959.5K | 446.6K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 1.13% |
| EPS Growth | N/A | ★ 20.09 |
| EPS | N/A | ★ 3.84 |
| Revenue | N/A | ★ $977,886,000.00 |
| Revenue This Year | N/A | $12.20 |
| Revenue Next Year | N/A | $10.73 |
| P/E Ratio | ★ N/A | $13.86 |
| Revenue Growth | N/A | ★ 15.70 |
| 52 Week Low | $7.58 | $44.26 |
| 52 Week High | $112.64 | $90.34 |
Technical Indicators
Market Signals| Indicator | CELC | TGLS |
|---|---|---|
| Relative Strength Index (RSI) | 63.75 | 55.00 |
| Support Level | $100.00 | $50.99 |
| Resistance Level | $112.64 | $54.73 |
| Average True Range (ATR) | 5.11 | 1.47 |
| MACD | -1.00 | 0.93 |
| Stochastic Oscillator | 36.57 | 76.23 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About TGLS Tecnoglass Inc.
Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.